NVAX

Business Context and Reporting Period

Company: NOVAVAX INC
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2007
Business Overview: Novavax is a biopharmaceutical company transitioning from a specialty pharmaceutical focus to developing vaccines using proprietary Virus-Like Particle (VLP) technology and micellar nanoparticle (MNP) drug delivery platforms. Key product candidates include vaccines for avian and seasonal influenza. The company also manufactures ESTRASORB, an FDA-approved estrogen replacement product, under a supply agreement with Esprit Pharma, Inc.

Key Financial Metrics

Note: Figures are in thousands except per share data. Short-term investments were $0 in Q1 2006.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 49% to $668,000 from $1.3 million. This was driven by a 77% drop in ESTRASORB sales ($153k vs $657k) and a 53% decline in contract research revenue ($222k vs $474k), partially offset by growth in Gynodiol sales.
• Increased Operating Expenses: Total operating costs rose 52% to $9.7 million.
  • R&D Expenses: Increased 82% to $3.7 million due to expanded preclinical testing and process development for influenza vaccine candidates.
  • SG&A Expenses: Increased 67% to $4.6 million. A significant portion ($1.0 million) was due to reserves established for notes receivable from two former directors, alongside increased facility costs for the new Rockville, MD headquarters.
• Manufacturing Losses: The company continues to manufacture ESTRASORB at a loss due to idle capacity costs ($791,000 in Q1 2007 vs $400,000 in Q1 2006) and selling prices below manufacturing costs.
• Interest Income: Net interest income turned positive ($604k) compared to a net expense in 2006, driven by higher investment balances from equity financing in 2006.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current capital resources ($67.6 million in cash and investments) are sufficient to sustain operations into 2008. If convertible notes are redeemed (triggered if stock price remains below $5.46 for 30 of 40 trading days prior to July 2007), resources may only last into the second half of 2008 without new financing.
• Strategic Focus: Continued investment in VLP vaccine development for pandemic influenza (H5N1, H9N2) and seasonal influenza. The company is seeking collaborations or licensing deals to fund development.
• Key Risks:
  • Manufacturing Economics: ESTRASORB production remains unprofitable until volumes increase or facility utilization improves. Negotiations on packaging and lease costs could materially impact results.
  • Related Party Receivables: Significant reserves ($1.0 million) were recorded for notes from former directors due to declining stock prices reducing the value of pledged collateral.
  • Regulatory and Clinical Risk: No assurance that vaccine candidates will receive FDA approval or be commercially successful.
  • Debt Redemption: Potential redemption of $22 million in senior convertible notes could adversely affect cash position.

Investor Verification Checklist

• Convertible Note Redemption Risk: Verify the current stock price trend relative to the $5.46 conversion price to assess the likelihood of note redemption in July 2007.
• Director Note Receivables: Confirm the status of the $1.3 million in notes receivable from former directors and the sufficiency of the pledged collateral given recent stock price volatility.
• ESTRASORB Economics: Monitor progress on negotiations for packaging costs and lease agreements, as well as any new contract manufacturing deals to offset idle capacity costs.
• Cash Burn Rate: Assess the sustainability of the current cash position ($67.6M) against the quarterly operating loss of $8.4M and the timeline for potential new equity financing.
• Grant Repayment: Verify the repayment schedule for the $400,000 Pennsylvania Opportunity Grant, with the first payment due May 1, 2007.